

# CUI Fuqiang Biographical Sketch

## **Name: CUI Fuqiang**

Nationality: China

Birth Date: Sep 15, 1971

Birth Place: Gansu, China

## **Position Title**

Professor and Director of Vaccine Research Center, School of Public Health, Peking University

Dr. **Cui Fuqiang** received his training at Lanzhou University, China (MD, 1990-1995), Hebrew University, Israel (MPH, 2003-2004), Basel University, Switzerland (PhD, 2010-2012), National University of Singapore, Singapore and Harvard University, USA (MPM, 2014-2015). He worked at the Gansu provincial Center for Disease Control and Prevention (CDC) between 1995 and 2005, and worked in China CDC between 2005 and 2016, mainly in the National Immunization Programme (2005-2016). He joined Peking University in November 2016. Since 2019, he has been working in WHO HQ, as the strategic information on hepatitis. Currently, he is the professor and Head of Laboratorial Science and Technology, School of Public Health, Peking University and Director of Vaccine Research Center, School of Public Health, Peking University. His research interests are infectious diseases, its epidemiology and prevention, mainly focuses on vaccine preventable diseases, epidemiological research on vaccines and vaccination, immunization intervention, international cooperation, global health. Prof. **Cui** is an author of over 280 scientific articles published in JAMA, International Journal of Epidemiology, Emerging Infectious Diseases, Journal of viral Hepatitis, Journal of Infectious Diseases, Vaccine, etc. Prof. Cui is also the PhD student mentor in Public Health and Epidemiology in Peking University and Chinese Center for Disease Control and Prevention. In addition, Cui currently serves as an Expert Resource Panel of hepatitis B in WHO Western Pacific Region and as a member of working group of Hepatitis A vaccine under Strategies Advisory Group Expert in WHO HQ. Prof. Cui involved emergency response in 2008 earthquake in Sichuan, pandemic 2009 Influenza A (H1N1), national mass measles vaccine campaigns in 2010, responded to polio outbreak in Xinjiang in 2011. He is the key person in leading the research team on 10th, 11th and 12th Five Year Plan of National Key Research Project of Science and Technology on infectious diseases in China. He has also experienced in working with NGOs and international Organizations. Between Aug 2019 to Aug 2020, He was the technical officer in WHO HQ, responsible for development of strategic information on hepatitis, and then work with WHO as the consultant continually .

## Education/Training

Institution and location	Degree	MM/YY	Field of study
Kennedy School of Governance, Harvard University	MPM	Jan, 2015- May 2015	Public Management
Lee Kuan Yew School of Public Policy, National University of Singapore (Jointed with Kennedy School, Harvard University)	MPM	Aug, 2014- July 2015	Public Management
Swiss Tropical & Public Health Institute, Basel University, Switzerland	PhD	Sep,2010 – Jan, 2012	Epidemiology
School of Public Health, Hebrew University, Israel	Master	Oct,2003 – Sep, 2004	Public Health
School of Public Health, Lanzhou University	Bachelor	Sep, 1990 – June,1995	Preventive Medicine

### A. Personal Statement

Learning is the foundation for working. I received training both in domestic and abroad, and have experienced working in provincial, national regional and international levels, such experiences enriched me with comprehensive and mature thoughts. I used to be the manager of China Global Alliance on Vaccines and Immunization (GAVI) project (2005-2012), which had enabled me having a big view to manage the international project and coordinate with multiple partners, particularly in making a good decision in a complex situation. I have been working on 10th, 11th and 12th Five Year Plan of National Key Research Project of Science and Technology on AIDS and Hepatitis in China for more than 15 years, such research experiences taught me to think and write in an independently and critically manner. I pursue the truth, I hope to find real reason among many complex phenomena in real life.

Experience inspires me to work efficiently. My education backgrounds give me the tools in managing public health programme, having the ability to translate the epidemiological data into policy practice, and knowing how to communicate with stakeholders and mobilize the social resources. What I have learned not only equipped me the information, but also knowledge, wisdom and skill, I believe I should be able to handle the complex situation both at national and international level.

Research prompts thinking intently. I have published over 280 scientific articles in Infectious Diseases, Emerging infectious diseases, Epidemiology, Public Health, Health Economy and emergency response. All these publications demonstrate my strong capability in epidemiology research, programme evaluation, and programme management in the diversity context both at national and international level. Learning during working is a good way to enable me to update my knowledge, I gained a lot from what I worked, taught and participated. I am the mentor of postdoctoral student

and master student in Public Health and advisor to China Field Epidemiology Training Programme in Chinese Center for Disease Control and Prevention as well. Research gives me not only data, information and knowledge, but also inspiration and wisdom. With research experience, I enabled to serve as an Expert Resource Panel of hepatitis B in WHO Western Pacific Region and as a member of working group of hepatitis A Vaccine under Strategies Advisory Group Expert in WHO HQ. And because of these participations, I have gained valuable knowledge from sharing and communication. Moreover, many of my publications have been cited by WHO as the examples of good practice in reducing inequity, establishing disease surveillance system and demonstrating the good impact of interventions. I had also contributed to WHO Guideline Development of “Introducing and Strengthening Hepatitis B Birth Dose Vaccination”, “Technical Considerations and Case Definitions to improve surveillance for Viral Hepatitis”.

In summary, I am good at Research Design, Epidemiology, Public Health, Project Management, as a specialist in communicable diseases management, with enriched experience in field investigation, programme evaluation, emergency response to infectious outbreaks and pandemic response, knowing how to work with governments, NGOs and international Organizations. I should be confidence to take any new jobs and make difference in the future, practically for strategic information and policy development.

## **B. Positions and Honors**

- President of steering committee on prompting hepatitis elimination, Chinese Preventive Medicine Association (2021-)
- President of hepatitis control branch, Chinese Vaccine Association (2021-2025)
- Vice President of Study Society of Infectious Disease Control, Chinese Preventive Medicine Association (2017-2020)
- Acting Chief Editor, Chinese Journal of Preventive Medicine (2019-)
- Associate editor, Chinese Journal of Virologic Diseases (2019-)
- Member of Strategic Advisory Group of Experts on Immunization (SAGE) Working Group on hepatitis A Vaccine, WHO HQ (Sep 2020-Dec 2020)
- Member of Standing Committee, Study Society of Laboratory Science and Technology, Chinese Preventive Medicine Association (2017-2020)
- Member of Standing Committee, Study Society of Public health Management in Clinical Institution, Chinese Preventive Medicine Association (2017-2020)
- Member of Standing Committee, Study Society of Vaccine and Immunization, Chinese Preventive Medicine Association (2017-2020)
- Vice President of Youth Committee of Global Health, Chinese Preventive Medicine Association (2017-2020)

- Expert of Consultative Committee on Life Science and Human Health for China Association for Science and Technology (2016-2020)
- Expert Resource Panel of hepatitis B in WHO Western Pacific Region (2015-2019)
- Vice Chair of Youth Committee of Public Health branch, the Chinese Medical Association (2015-2017).
- Nominated as the member of IHR expert panel, WHO HQ in 2015
- Expert Committee of Medicine Price Review of National development and reform committee of China (2012-2015)
- Member of Strategic Advisory Group of Experts on Immunization (SAGE) Working Group on the Decade of Vaccines, WHO HQ (2012-2015)
- Expert of Global Viral Hepatitis Network, WHO HQ (2012)
- Technical Advisory Group member of 21th EPI conference of WPRO in 2012 (represented for Lei Zhenglong)
- Secretary of China National Immunization Consultant Expert Advisory Group (2009-2012), WPRO
- Member of Experts committee of Chinese Foundation for Hepatitis B Prevention and Control (2009-2012) (2013-2016)
- Member of Advisory Board of The Lancet infectious Disease in Chinese
- Member of Advisory Board of Vaccine in Chinese
- Standing Member of Advisory Board of Chinese Journal of Vaccines and Immunization
- Standing member of Youth Committee of Public Health branch, the Chinese Medical Association (2013-2015).
- Member of Public Health Committee of China's health economic society

## **Positions and Employment**

### August 2020 to present

- Professor, Vaccine Research Center, School of Public Health, Peking University

### August 2019 to Aug 2020

- Technical officer, World Health Organization (P5)

### November 2016 to August 2019

- Professor, Head of Laboratorial Science and Technology, School of Public Health, Peking University

### December 2011 - November 2016

- Senior researcher/Epidemiologist/Professor of Epidemiology and Deputy Director of National Immunization Program, Chinese Center for Disease Control and Prevention

### June 2005 – 2011

- Manager, Ministry of Health, China/Global Alliance for Vaccine and Immunization (GAVI) Project
- Director, Division of Hepatitis, National Immunization Program, Chinese Center for Disease Control and Prevention

June 2001- June 2005

- Acting director and Deputy Director, Department of immunization, Gansu Provincial Center for Disease Control and Prevention

June 1995 - June 2001

- Medical officer, Department of immunization, Gansu Provincial Center for Disease Control and Prevention

**Honors and Awards**

- Third Class Award, Research Award of the Huaxia medical science and technology award in 2017
- Second Class Award, Research Award of the Association of Prevention Medicine of China, 2017
- Second Class Award, Research Award of the Association of Prevention Medicine of China, 2011
- The Excellent professional Recognition against polio outbreak response in Xinjiang in 2011, Ministry of Health, China.
- Excellent Staff Award of China CDC in 2007, 2008, 2009, 2010 and 2011
- Scholarship of Lee Kuan Yew, National University of Singapore.

**Books Published**

1. CUI Fuqiang. Sanitary microbiology. Peking University Medical Press, 2020. Beijing.
2. CUI Fuqiang, YANG Huan. Post market clinical research and evaluation of vaccines. Peking University Medical Press, 2020. Beijing.
3. LIU Shelan, CHEN Enfu, CUI Fuqiang. Respiratory syncytial virus infection. The Science Publishing Company, 2018, Beijing.
4. FENG Zijian, CUI Fuqiang. Epidemiology in public health practice. People's medical publishing house.

**C. Peer-reviewed Publications**

1. Zheng Hui, Shevanthi Nayagam, Polin Chan, Wang Fuzhen, Mark Thursz, Yin Zundong, Miao Ning, Sun Xiaojin, Fuqiang Cui, Zhang Guomind & Timothy B Hallett. Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis. Bull World Health Organ 2020;98: | doi: <http://dx.doi.org/10.2471/BLT.19.248146>.
2. Cui F. Strategies to increase timely uptake of hepatitis B vaccine birth dose. Lancet

- GH, 2020, Vol 8 July 2020, e869.
3. Han B, Zhao T, Liu B, Liu H, ..., Cui F. Public awareness, individual prevention practice and psychological effect at the beginning of the COVID-19 outbreak in China. *Journal of Epidemiology* 2020. <https://doi.org/10.2188/jea.JE20200148>
  4. Wang S, Han B, Wan Y, Liu J, Zhao T, Liu H, Cui F. Do male university students know enough about human papillomavirus (HPV) to make informed decisions about vaccination? *Med Sci Monit*, 2020; 26: e924840. DOI: 10.12659/MSM.924840.
  5. Zheng H, Zhang G, Wang F, Yin Z, Miao N, Sun X, Liang X, Cui F. Self-motivated medical care-seeking behaviors and disease progression in a community-based cohort of chronic hepatitis B virus-infected patients in China. *BMC public health*. 2019 Dec 1;19(1):901.
  6. Yuan Q, Wang F, Zheng H, Zhang G, Miao N, Sun X, et al. Hepatitis B vaccination coverage among health care workers in China. *PLoS ONE* 2019, 14(5): e0216598. <https://doi.org/10.1371/journal.pone.0216598>.
  7. Han B, Wang S, Wan Y, Liu J, Zhao T, Cui J, Zhuang H, Cui F. Has the public lost confidence in vaccines because of a vaccine scandal in China. *Vaccine*. 2019 Aug 23;37(36):5270-5.
  8. Li HJ, Du J, Yang YN, Cui Y, Xi L, Wang S, Liu YQ, Zhang GF, Cui F, Lu QB. Outbreak of Human Parainfluenza Virus Type 1 in a Kindergarten from China, 2018. *Journal of Pediatric Infectious Diseases*. 2020,15(01):025-30.
  9. Cui F, Woodring J, Chan P, Xu F. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. *International Journal of Epidemiology*, 2018, 1–9. doi: 10.1093/ije/dyy077
  10. Han B, Yuan Q, Shi Y, et al. The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China. *Plos One*, 2018, 13(4):e0195455. (Corresponding Author).
  11. Zheng H, Cui FQ, Wang FZ, et al. The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China. *J Viral Hepat*. Jan 2018;25(1):88-96. (Co-First author).
  12. Wang F, Zheng H, Zhang G, et al. Effectiveness of prevention of mother-to-child transmission practice in three provinces of Southern China. *Hum Vaccin Immunother*, 2015, 11(8):2061-2067. doi: 10.1080/21645515.2015.1023972. PMID:26090956 (Corresponding Author).
  13. Cui F, Liang X, Wang F, Zheng H, Hutin Y, Yang W. Chinese Experience with Development, Production and Post-marketing Surveillance of Hepatitis A vaccines. *J Epidemiol*, 2014, 24 (2):169-177.
  14. Wang F, Zhang G, Zheng H, et al. Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China[J]. *Vaccine*, 2017, 35(33):4229-4235. doi: 10.1016/j.vaccine.2017.06.019. Epub 2017 Jun 23. (Corresponding author)
  15. Zheng H, Cui F, Wang F, et al. The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China. *J Viral Hepat*. 2017,00:1–9. (first coauthor)

16. Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, Sun X, Miao N, Yin Z, Feng Z, Liang X, Wang Y. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. *Emerg Infect Dis.* 2017 May;23(5):765-772. doi: 10.3201/eid2305.161477.
17. Wang FZ, Zheng H, Liu JH, Sun XJ, Miao N, Shen LP, Zhang GM, Cui FQ. The coverage of hepatitis A vaccine among 2-29 year olds and the reporting incidence of hepatitis A, 2014, China. *Chin Journal of Epidemiol*, 2016,37(8):1099-1104. (Corresponding Author)
18. Wang FZ, Zhang GM, Shen LP, Liu JH, Zheng H, Wang F, Miao N, Sun XJ, Liang XF, Cui FQ. [Epidemiological characteristics of children aged 1-4 years without timely birth dose of hepatitis B vaccine vaccination in China, 2014]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2017 Jan 10;38(1):32-36. doi: 10.3760/cma.j.issn.0254-6450.2017.01.006. in Chinese.
19. Feng Y, Shi J, Gao L, Yao T, Feng D, Luo D, Li Z, Zhang Y, Wang F, Cui F, Li L, Liang X, Wang S. Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: A randomized, open-labeled, blank-controlled trial. *Hum Vaccin Immunother.* 2017 Mar 16:1-7. doi: 10.1080/21645515.2017.1283082. [Epub ahead of print] PMID: 28301282
20. Liu T, Wang F, Zhang S, et al. Whole-gene analysis of two groups of hepatitis B virus C/D inter-genotype recombinant strains isolated in Tibet, China.[J]. *Plos One*, 2017, 12(6):e0179846.
21. Zu J, Zhuang G, Liang P, Cui F, Wang F, Zheng H, et al. Estimating age-related incidence of HBsAg seroclearance in chronic hepatitis B virus infections of China by using a dynamic compartmental model.[J]. *Scientific Reports*, 2017, 7(1):2912.
22. Miao N, Zhang GM, Wang FZ, Zheng H, Sun XJ, Ma XJ, Cui FQ. [Consistency analysis on acute hepatitis B inpatients reported by hepatitis B surveillance pilot spots in six provinces of China]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2017 Feb 10;38(2):216-220. doi: 10.3760/cma.j.issn.0254-6450.2017.02.016. Chinese.
23. Yin WJ, Shen LP, Wang FZ, Zhang GM, Zheng H, Wang F, Liu TZ, Meng QL, Yi Y, Cui FQ, Bi SL. Hepatitis B Immunoprophylactic Failure and Characteristics of the Hepatitis B Virus Gene in Mother-Infant Pairs in Parts of China. *Biomed Environ Sci.* 2016 Nov;29(11):790-801. doi: 10.3967/bes2016.106.
24. Wang H, Cai B, Rao D, Liu M, Li Y, Liang X, Cui F, Zhang G, Wang F, Pang X, Nie L, Qiu Q, Wu J, Li L, Huang F, Zhang W. Rapid immunization effects of a new type of 60 µg hepatitis B vaccine compared with traditional 20 µg hepatitis B vaccines in adults. *Hum Vaccin Immunother.* 2016 Nov;12(11):2921-2926.
25. Zhang X, An J, Tu A, Liang X, Cui F, Zheng H, Tang Y, Liu J, Wang X, Zhang N, Li H. Comparison of immune persistence among inactivated and live attenuated hepatitis B vaccines 2 years after a single dose. *Hum Vaccin Immunother.* 2016 Sep;12(9):2322-6. doi: 10.1080/21645515.2015.1134069. Epub 2016 Aug 5.
26. Liu T, Shen L, Yin W, Wang F, Wang F, Zhang G, Zheng H, Dunzhu D, Bi S, Cui F. [Whole-sequence Analyses for 12 HBV C/D Recombinants from a Population in Tibet (China)]. *Bing Du Xue Bao.* 2016 Mar;32(2):156-60. Chinese.

27. Zhang L, Yan BY, Lyu JJ, Liu JY, Feng Y, Wu WL, Cao CZ, Chen SY, Zhou LB, Liang XF, Cui FQ, Wang FZ, Zhang GM, Xu AQ. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among non-responsive adults: a 4-year of follow-up study]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2016 Jun;50(6):497-502. doi: 10.3760/cma.j.issn.0253-9624.2016.06.005. Chinese.
28. Lyu JJ, Yin XW, Yan BY, Liu JY, Feng Y, Wu WL, Chen SY, Zhou LB, Liang XF, Cui FQ, Wang FZ, Zhang L, Xu AQ. [Anti-HBs persistence following revaccination with three doses of hepatitis B vaccine among low-responsive adults after primary vaccination: a 4-year follow-up study]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2016 Jun;50(6):491-6. doi: 10.3760/cma.j.issn.0253-9624.2016.06.004. Chinese.
29. Wu WL, Yan BY, Lyu JJ, Liu JY, Feng Y, Chen SY, Zhou LB, Liang XF, Cui FQ, Wang FZ, Zhang GM, Zhang L, Xu AQ. [Antibody persistence following primary vaccination with hepatitis B vaccine among normal and high-responder adults: a 5-year follow-up study]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2016 Jun;50(6):484-90. doi: 10.3760/cma.j.issn.0253-9624.2016.06.003. Chinese.
30. Lyu JJ, Zhang L, Yan BY, Liu JY, Feng Y, Song LZ, Chen SY, Zhou LB, Liang XF, Cui FQ, Wang FZ, Xu AQ. [Anti-HBs persistence following primary vaccination with three doses of hepatitis B vaccine among normal and high-responder adults: a 3-year follow-up study]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2016 Jun;50(6):478-83. doi: 10.3760/cma.j.issn.0253-9624.2016.06.002. Chinese.
31. Yue C, Sun X, Wei N, Yu W, Cui F, Wang H, Li L, Zhang L, Shi G, An Z. Quick assessment of the influence of the Hepatitis B vaccine event on children's vaccination. *Hum Vaccin Immunother*. 2016 Oct 2;12(10):2611-2615. doi: 10.1080/21645515.2016.1187351. Epub 2016 May 31.
32. Zheng H, Wang FZ, Zhang GM, Wu ZH, Miao N, Sun XJ, Wang HQ, **Cui FQ**, Liang XF. Study on health-seeking behavior and influencing factors among Chinese Hepatitis B surface antigen positive adults. *Chin Journal of Epidemiol*, 2016,37(4):455-458. (Corresponding Author)
33. Zheng H, Wang FZ, Zhang GM, Miao N, Sun XJ, **Cui FQ**. Analysis on Duplicate Report of Hepatitis B in National Notifiable Disease Report System in China During 2011-2013. *Chin Journal of Epidemiol*, 2016,37(9):1248-1252. (Corresponding Author)
34. Yu W, Liu D, Zheng J, Liu Y, An Z, Rodewald L, Zhang G, Su Q, Li K, Xu D, Wang F, Yuan P, Xia W, Ning G, Zheng H, Chu Y, Cui J, Duan M, Hao L, Zhou Y, Wu Z, Zhang X, **Cui F**, Li L, Wang H. Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China, *International Journal of Epidemiology*, 2016,45(2): 441–449. doi: 10.1093/ije/dyv349.
35. Liang P, Zu J, Yin J, Li H, Gao L, **Cui F**, et al. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992-2006: A mathematical model analysis. *J Theor Biol*. 2015; 386: 115-21.
36. Wang F, Shen L, Cui F, Zhang S, Zheng H, Zhang Y, et al. The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China. *Vaccine*. 2015; 33(23): 2704-9.



37. Zheng H, Wang FZ, Zhang GM, Cui FQ, Wu ZH, Miao N, et al. An economic analysis of adult hepatitis B vaccination in China. *Vaccine*. 2015; 33(48): 6831-9.
38. Zhang S, Ma Q, Liang S, Xiao H, Zhuang G, Zou Y, Tan H, Liu J, Zhang Y, Zhang L, Feng X, Xue L, Hu D, Cui F, Liang X. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. *J Viral Hepat*. 2016; 23(3): 202-10.
39. Kang G, Ma F, Chen H, Yang Y, Guo S, Wang Z, Liang X, Li L, Cui F, Zhang L. Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers. *Vaccine*. 2015; 33(33): 4093-9.
40. Chen YS, Zheng H, Liu YM, Wang FZ, Wu ZH, Miao N, Sun XJ, Zhang GM, Cui FQ, Liang XF. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013. *Hum Vaccin Immunother*. 2016 Feb 18:1-9. [Epub ahead of print] No abstract available. PMID: 26891075.
41. Feng Y, Shi J, Gao L, et al. Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: A randomized, open-labeled, blank-controlled trial. *Hum Vaccin Immunother*. Jun 3 2017;13(6):1-7.
42. Lyu JJ, Yan BY, Liu JY, et al. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among low-responder infants following primary vaccination: 4-year of follow-up]. *Zhonghua Yu Fang Yi Xue Za Zhi*. Jun 6 2017;51(6):490-495.
43. Ma QS, Liang S, Xiao HW, et al. [Survey of economic burden of hepatitis B-related diseases in 12 areas in China]. *Zhonghua Liu Xing Bing Xue Za Zhi*. Jul 10 2017;38(7):868-876.
44. Wang FZ, Zheng H, Miao N, et al. [Analysis on sero-epidemiological characteristics of hepatitis B virus among people born during 1994-2001 before and after hepatitis B vaccine catch-up vaccination, China]. *Zhonghua Yu Fang Yi Xue Za Zhi*. Jun 6 2017;51(6):469-474.
45. Wang FZ, Zheng H, Zhang GM, Miao N, Sun XJ, Cui FQ. [Sero-epidemiological analysis on hepatitis B among children aged 1-14 years old born to HBsAg positive mother in China, 2014]. *Zhonghua Liu Xing Bing Xue Za Zhi*. Apr 10 2017;38(4):457-461.
46. Zhang L, Zhang W, Lyu JJ, et al. [Comparison of antibody persistence after primary immunization with 5 mug and 10 mug recombinant hepatitis B vaccine among newborns with normal and high response: a five-year following-up]. *Zhonghua Liu Xing Bing Xue Za Zhi*. Sep 10 2017;38(9):1156-1160.
47. Zhao D, Gai Tobe R, Cui M, He J, Wu B. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. *Vaccine*. Dec 7 2016;34(50):6158-6165.
48. Valdivieso F, Gonzalez C, Najera M, et al. Knowledge, attitudes, and practices regarding hantavirus disease and acceptance of a vaccine trial in rural communities of southern Chile. *Hum Vaccin Immunother*. Apr 3 2017;13(4):808-815.

49. Gao S, Zeng L, Zhang X, et al. Attenuated *Streptococcus pneumoniae* vaccine candidate SPY1 promotes dendritic cell activation and drives a Th1/Th17 response. *Immunol Lett.* Nov 2016;179:47-55.
50. Sheng Z, Gao N, Cui X, et al. Electroporation enhances protective immune response of a DNA vaccine against Japanese encephalitis in mice and pigs. *Vaccine.* Nov 11 2016;34(47):5751-5757.
51. Zhou L, Cui FQ, Pan Y. [Recognition of the vaccination: a key and important strategy in controlling vaccine preventable diseases]. *Zhonghua Yu Fang Yi Xue Za Zhi.* Sep 6 2016;50(9):755-758.
52. Wang H, Cai B, Rao D, et al. Rapid immunization effects of a new type of 60 mug hepatitis B vaccine compared with traditional 20 mug hepatitis B vaccines in adults. *Hum Vaccin Immunother.* Nov 2016;12(11):2921-2926.
53. Wu D, Yen C, Yin ZD, et al. The Public Health Burden of Rotavirus Disease in Children Younger Than Five Years and Considerations for Rotavirus Vaccine Introduction in China. *Pediatr Infect Dis J.* Dec 2016;35(12):e392-e398.
54. Wang FZ, Zheng H, Liu JH, et al. [The coverage of hepatitis A vaccine among 2-29 year olds and the reporting incidence of hepatitis A in China, 2014]. *Zhonghua Liu Xing Bing Xue Za Zhi.* Aug 10 2016;37(8):1099-1104.
55. Zhang L, Yan BY, Lyu JJ, et al. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among non-responsive adults: a 4-year of follow-up study]. *Zhonghua Yu Fang Yi Xue Za Zhi.* Jun 2016;50(6):497-502.
56. 10. Lyu JJ, Yin XW, Yan BY, et al. [Anti-HBs persistence following revaccination with three doses of hepatitis B vaccine among low-responsive adults after primary vaccination: a 4-year follow-up study]. *Zhonghua Yu Fang Yi Xue Za Zhi.* Jun 2016;50(6):491-496.
57. Wu WL, Yan BY, Lyu JJ, et al. [Antibody persistence following primary vaccination with hepatitis B vaccine among normal and high-responder adults: a 5-year follow-up study]. *Zhonghua Yu Fang Yi Xue Za Zhi.* Jun 2016;50(6):484-490.
58. Lyu JJ, Zhang L, Yan BY, et al. [Anti-HBs persistence following primary vaccination with three doses of hepatitis B vaccine among normal and high-responder adults: a 3-year follow-up study]. *Zhonghua Yu Fang Yi Xue Za Zhi.* Jun 2016;50(6):478-483.
59. Yue C, Sun X, Wei N, et al. Quick assessment of the influence of the Hepatitis B vaccine event on children's vaccination. *Hum Vaccin Immunother.* Oct 2 2016;12(10):2611-2615.
60. Yin WJ, Shen LP, Wang FZ, et al. Hepatitis B Immunoprophylactic Failure and Characteristics of the Hepatitis B Virus Gene in Mother-Infant Pairs in Parts of China. *Biomed Environ Sci.* Nov 2016;29(11):790-801.
61. Zheng H, Wang FZ, Zhang GM, Miao N, Sun XJ, Cui FQ. [Analysis on duplicate reporting of hepatitis B in national notifiable communicable disease report system in China, 2011-2013]. *Zhonghua Liu Xing Bing Xue Za Zhi.* Sep 10 2016;37(9):1248-1252.

62. Zhang X, An J, Tu A, et al. Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. *Hum Vaccin Immunother.* Sep 2016;12(9):2322-2326.
63. Yu W, Liu D, Zheng J, et al. Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China. *Int J Epidemiol.* Apr 2016;45(2):441-449.
64. Zheng H, Wang F, Zhang G, et al. [Study on health-seeking behavior and influencing factors among Chinese hepatitis B surface antigen positive adults]. *Zhonghua Liu Xing Bing Xue Za Zhi.* Apr 2016;37(4):455-459.
65. Chen YS, Zheng H, Liu YM, et al. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013. *Hum Vaccin Immunother.* Jul 2 2016;12(7):1838-1846.
66. Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. *J Viral Hepat.* Mar 2016;23(3):202-210.
67. Wang HB, Yu WZ, Wang XQ, Wushouer F, Wang JP, Wang DY, **Cui FQ**, Zheng JS, Wen N, Ji YX, Fan CX, Wang HL, Ning GJ, Huang GH, Yan DM, Su QR, Liu DW, Zhang GM, Reilly KH, Ning J, Fu JP, Mi SS, Luo HM, Yang WZ. An outbreak following importation of wild poliovirus in Xinjiang Uyghur Autonomous Region, China, 2011. *BMC Infect Dis.* 2015 Jan 31;15:34. doi: 10.1186/s12879-015-0761-y. PMID: 25636581
68. Zhang L, Yan B, Liu J, Lyu J, Feng Y, Xu A, Song L, Liang X, Li L, Cui F, Zhang G, Wang F. [Persistence of immune memory to hepatitis B vaccine among infants with normal or high antibody response to primary vaccination: a five-year following-up study]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2015 Dec;36(12):1372-6. Chinese.
69. Liang P, Zu J, Yin J, Li H, Gao L, **Cui F**, Wang F, Liang X, Zhuang G. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992-2006: A mathematical model analysis. *Journal of theoretical biology*, 2015, 386: 115-121.
70. Zhang L, Liu J, Lu J, Yan B, Song L, Li L, **Cui F**, Zhang G, Wang F, Liang X, Xu A. Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China. *Human Vaccines & Immunotherapeutics*, 2015, 11(11): 2716-2722.
71. Kang G, Ma F, Chen H, Yang Y, Guo S, Wang Z, Liang X, Li L, **Cui F**, Zhang L. Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers. *Vaccine.* 2015 Aug 7;33(33):4093-9. doi: 10.1016/j.vaccine.2015.06.081. Epub 2015 Jul 3. PMID: 26144895
72. Xiao M, Qiu Q, Pang X, Liang X, Li L, **Cui F**, Wang F, Zhang G, Li H, Wang L, Zhang W. Immune response in infants after universal high-dose hepatitis B vaccination: A community-based study in Beijing, China. *Vaccine*, 2015, 33(43): 5878-5883. doi: 10.1016/j.vaccine.2015.06.018. [Epub ahead of print] PMID: 26117148

73. Yin J, Ji Z, Liang P, Wu Q, **Cui F**, Wang F, Liang X, Zhuang G. The doses of 10 µg should replace the doses of 5 µg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. *Vaccine*. 2015 Jul 17;33(31):3731-8. doi: 10.1016/j.vaccine.2015.05.082. Epub 2015 Jun 6. PMID: 26057138
74. Wang F, Shen L, **Cui F**, Zhang S, Zheng H, Zhang Y, Liang X, Wang F, Bi S. The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China. *Vaccine*. 2015 May 28;33(23):2704-9. doi: 10.1016/j.vaccine.2015.03.064. Epub 2015 Apr 2. PMID:25843269
75. Wang F, Zheng H, Zhang G, et al. Effectiveness of prevention of mother-to-child transmission practice in three provinces of Southern China.[J]. *Human Vaccines & Immunotherapeutics*, 2015, 11(8):2061-2067.
76. Wen N, Fan CX, Fu JP, Ning J, Ji YX, Luo HM, Wang HQ, Zhu SL, Yu WZ, Wang HB, Zhu H, **Cui FQ**, Li DX, Wang SW, Xu WB, Hao LX, Cao LS, Luo L, Han L, Cao L, Xia W, Wang XQ, Reilly KH, Wushouer F, Mi SS, Yang WZ, Li L. Enhanced surveillance of acute flaccid paralysis following importation of wild poliovirus in Xinjiang Uygur Autonomous Region, China. *BMC Infect Dis*. 2014 Feb 27;14:113. doi: 10.1186/1471-2334-14-113. PMID:
77. Yan B, Lyu J, Liu J, Feng Y, Xu A, Chen S, Zhou L, Liang X, **Cui F**, Wang F, Zhang L. [Antibody persistence following booster vaccination with three doses of hepatitis B vaccines among low-response adults in Zhangqiu county of Shandong province: 24-month of follow-up from 2009]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2014 Dec;48(12):1043-7. Chinese. PMID:25619213
78. Jia Y, Li L, **Cui F**, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N, Sun X, Zhang L, Lv J, Yang F. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. *Hum Vaccin Immunother*. 2014;10(10):2983-91. doi: 10.4161/hv.29944. PMID:25483678
79. Zhou L, **Cui F**, Tang F. Newborns first hepatitis B vaccine inoculation situation, influencing factors and countermeasures. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2014 Jun;48(6):437-40. Chinese. No abstract available. PMID:25219427 (Corresponding Author)
80. Lei Z, **Cui F**. Vaccination plays an key role to improve health of population in battling with vaccine preventable disease. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2014 Jun;48(6):433-6. Chinese. No abstract available. PMID:25219426 (Corresponding Author)
81. Shen L, Yin W, Zheng H, **Cui F**, Zhang S, Wang F, Wang F, Zhang Y, Liang X, Bi S. Molecular epidemiological study of hepatitis B virus genotypes in Southwest, China. *J Med Virol*. 2014 Aug;86(8):1307-13. doi: 10.1002/jmv.23965. Epub 2014 May 5. PMID: 24797477
82. Jia Z, Yi Y, Liu J, Cao J, Zhang Y, et al. (2014) Epidemiology of Hepatitis E Virus in China: Results from the Third National Viral Hepatitis Prevalence Survey, 2005–2006. *PLoS ONE* 9(10): e110837. doi:10.1371/journal.pone.0110837 (Co-corresponding author)

83. Jia, Y. X., **F. Q. Cui**, et al. (2014). "Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B." *Quality of Life Research* 23(8): 2355-2363 (Corresponding author).
84. **Cui F**, Liang X, Wang F, Zheng H, Hutin Y, Yang W. Chinese Experience with Development, Production and Post-marketing Surveillance of Hepatitis A vaccines. *J Epidemiol.* 2014;24(3):169-77. Epub 2014 Mar 29.
85. **Cui F**, Yang W. The Immunization of hepatitis B Vaccine and adverse events following immunization, *Chinese Journal of Epidemiology*, 2014,35(1):1-2.
86. Wang F, Zheng H, Zhang G, Miao N, Chen Y, Wu Z, Sun Xn, Li L, Liang X, **Cui F**. Survey on Hepatitis B Virus Surface Antigen Screening among Pregnant Women and Prevention Measures for Newborns in 8 Provinces or Autonomous Regions,China[J].*Chinese Journal of Vaccines and Immunization*, 2014,20(6):523-528. (Corresponding Author)
87. Yu W, Yue C, Zhou Y; Zhang X, **Cui F**, Wang H, Li L. Health Education and Promotion Campaigns on National Expanded Program for Immunization in 2013[J].*Chinese Journal of Vaccines and Immunization*,2014,20(4):289-293.
88. Jiang Y, Yu W, Zhang X; Wang L, Zhou Y, Zhang X, An Z, Li K, Xu D, Wang H, Cui Y, **Cui F**, Li L. Public Confidence in Vaccination after the Hepatitis B Vaccine Event: Results from a Telephone Uurvey Survey[J]. *Chinese Journal of Vaccines and Immunization*, 2014,20(4):314-380. (Corresponding Author)
89. Wang F, **Cui F**. The Immunoprophylaxis Strategy of Prevention Mother to Child Transmission of Hepatitis B Virus[J]. *Chinese Journal of Vaccines and Immunization*, 2014,20(4):355-375. (Corresponding Author)
90. Zheng H, Wang F, Shen L; Zhang G, Wang F, Chen Y, Gong X, **Cui F**, Liang X. Study of the Relationship between Hepatitis B Virus Deoxyribonucleic Acid, Hepatitis B Virus e Antigen and Alanine Aminotransferase in Chronic Hepatitis B Patients[J]. *Chinese Journal of Vaccines and Immunization*, 2014,20(4):294-323. (Corresponding Author)
91. Zheng H, Wang F, Zhuang G, Zhang G, Chen Y, Gong X, **Cui F**, Liang X. Quality of Life among Chronic Hepatitis B Virus Infected People in their Communities [J]. *Chinese Journal of Vaccines and Immunization*, 2014,20(4):309-343.
92. Yu W, Li F, Zhang Z, Shan F, Liu B, Su Q, Yan J, Zhou Y, Sun l, Li K, Liu G, An Z, Xu D, Duan M, Zhang X, Chu R, **Cui F**, Wang H, Li L. Analysis of Parental Confidence on Vaccination after the Hepatitis B Vaccine Event Reported by the Media in 2013 in Some Provinces[J]. *Chinese Journal of Vaccines and Immunization*, 2014,20(3):233-236.
93. Su Q, Xu , Strebel P, Xu W, Hao L, Zhou Y, Li H, Pang X, Ma C, Zhang Y, Fang G, **Cui F**, Ding Z, Shen Y, An Z, Zhang Y, Xie S, Schluter W, Yu W, Zheng J, Xia W, Wang Q, Zheng H, Zhang Y, Zhang L, Yang W. National and International Experts' Consensus on Key Technical Issues of Measles Elimination in China[J]. *Chinese Journal of Vaccines and Immunization*, 2014,20(3):264-283.
94. Yue C, Zhou Y, Zhang X, Zhu X, Dun Z, Du W, Zhang X, Guang B, Fuer H, **Cui F**. Survey on the Children Guardians' Vaccination Knowledge Status and Analysis on Influencing Factors of Timely First Dose of Measles Attenuated Live Vaccine

- Vaccination in Western Poverty Area of China[J]. Chinese Journal of Vaccines and Immunization, 2014,20(2):109-154.
95. Xie R, Zhang D, Wang H, Yin D, Zheng J, Liu Q, Hao L, Yu W, Wen N, Zhang G, Li Y, Liu D, Xia W, Liu Y, Liu Y, Qi Q, Zhu J, Yang S, Zhang Q, Wang H, **Cui F**, Luo H, Fang G, Li L. Preliminary Assessment on Risk of Vaccine Preventable Diseases in Earthquake Area in Lushan,Sichuan Province[J]. Chinese Journal of Vaccines and Immunization,2014,20(2):160-164.
  96. Yue C, Sun X, Wei N, Guo C, Hao Z, Zhao J, Cui Z, Xiao L, Zhu X, Mo X, Yu W, Shi G, An Z, **Cui F**, Wang H, Li L. Quick Assessment on the Influence of Hepatitis B Vaccine Event Reported by Media to Children's Parents in 2013[J]. Chinese Journal of Vaccines and Immunization,2014,20(2):100-192.
  97. Zheng H, Du F, Chen X, Wang F, Zhang G, Chen Y, Miao N, Sun X, **Cui F**. Evaluation on Four Years' Protective Effects after Hepatitis A Mass Campaign in the Earthquake Areas in Sichuan Province,China [J]. Chinese Journal of Vaccines and Immunization,2014,20(1):40-44.
  98. Li J, Ren H, Xu A, Zhang L, Zhai X., Li Y, Yan B, Zhu Fi, Huang T, **Cui F**, Liang X, Li Y. Study of Response to Revaccination of Hepatitis B Vaccine (HepB) with Different Schedule and Different Doses for Non-response Infants after Primary Immunization with 5 $\mu$ g HepB Made by Recombinant Deoxyribonucleic Acid Techniques in Saccharomyces Cerevisiae [J]. Chinese Journal of Vaccines and Immunization,2014,20(1):31-35.
  99. Ma F, Liang X, Zhang L, Kang G, Yan S, **Cui F**, Dong C, Li L, Chen H, Yang Y. Immunogenicity of Different Doses of Hepatitis B Vaccine Made by Recombinant Deoxyribonucleic Acid Techniques in Saccharomyces Cereviside Yeast among Newborn and Infant[J]. Chinese Journal of Vaccines and Immunization,2013,19(6):485-491.
  - 100.Jia Y, **Cui F**; Zhang D. Investigation on the Applicability of EQ-5D-5L in Chinese Patients with Chronic Hepatitis B[J]. Chinese Journal of Vaccines and Immunization,2013,19(6):492-544.
  - 101.Xu Y, **Cui F**, Luo H, Pei Y, Ma H. Current situation on health education billboard set at bus stops of main roads in Beijing. Chin J Epidemiol, 2013,34(12):1266.
  - 102.Miao N, Zhang G, Wang F, Zheng H, Wu Z, Sun X, **Cui F**. The epidemiology analysis of Hepatitis E in 2004-2011 in China. Chinese Journal of Vaccines and Immunization, 2013, 19(5): 451-454. (corresponding author)
  - 103.Wang F, Zhang G, Zheng H, Gao P, Cao F, Jiang Z, Yan B, Fan J, Shao X, Chen X, Zhang X, Gong X, Chen Y, Sun X, Liang X, **Cui F**. Analysis on the hepatitis B cases reported by national notifiable disease reporting system in 18 pilot countries in China from 2008-2010. Chinese Journal of Vaccines and Immunization,2013,19(5):439-443. (corresponding author)
  - 104.Liang X, **Cui F**, Hadler S, et al. Origins, design and implementation of the China GAVI project. Vaccine 31S (2013) J8– J14.
  - 105.Kane M.A. Hadler S.C, Lee L, Shapiro C.N, **Cui F**, Wang X, Kumar R. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization. Vaccine 31S (2013) J15– J20.

106. Liang X, Bi S, Yang W, Wang L, Cui G, **Cui F**, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination. *Vaccine* 31S (2013) J21– J28.
107. **Cui F**, Liang X, Gong X, et al. Preventing hepatitis B through universal vaccination: Reduction of inequalities through the GAVI China project. *Vaccine* 31S (2013) J29– J35.
108. **Cui F**, Luo H, Wang F, et al. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: Results from GAVI Final evaluation. *Vaccine* 31S (2013) J36– J42.
109. Wu Z, **Cui F**, Chen Y, et al. Evaluation of immunization injection safety in China, 2010: Achievements, future sustainability. *Vaccine* 31S (2013) J43– J48. (corresponding author)
110. Hutin Y, Hennessey K, Cairns L, Zhang Y, Li H, Zhao L, **Cui F**, Lee L, Tan V, Takashima Y, Zuo S, Hadler S. Improving hepatitis B vaccine timely birth dose coverage: Lessons from five demonstration projects in China, 2005–2009. *Vaccine* 31S (2013) J49– J55.
111. **Cui F**, Li L, Hadler S, Wang F, Zheng H, Chen Y, Gong X, Hutin Y, Cairns L, Liang X, Yang W. Reprint of: Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992–200. *Vaccine* 31S (2013) J56– J61.
112. Hadler S, **Cui F**, Averhoff F, Taylor T, Wang F, Li L, Liang X, Yang W. The impact of hepatitis B vaccine in China and in the China GAVI Project. *Vaccine* 31S (2013) J66– J72.
113. Yang W, Liang X, **Cui F**, Li L, Hadler S, Hutin Y, Kane M, Wang Y. Key outcomes and addressing remaining challenges- Perspectives from a final evaluation of the China GAVI project. *Vaccine* 31S (2013) J73–J78.
114. **Cui F**, Drobeniuc J, Hadler S, Hutin YJ, Ma F, Wiersma S, Wang F, Wu J, Zheng H, Zhou L, Zuo S. Review of hepatitis B surveillance in China: Improving information to frame future directions in prevention and control. *Vaccine* 31S (2013) J79– J84.
115. Miao N, Jin L, Piao H, Chen L, Wang F, Chen Y, Zheng H, Wu Z, **Cui F**, Li L, Liang X. Study on Risk Factors of Hepatitis C Virus Infection in Yanbian Korean Prefecture. *Chinese Journal of Vaccines and Immunization*, 2013, 19(2) :159-163.
116. Luo HM, Zhang Y, Wang XQ, Yu WZ, Wen N, Yan DM, Wang HQ, Wushouer F, Wang HB, Xu AQ, Zheng JS, Li DX, Cui H, Wang JP, Zhu SL, Feng ZJ, **Cui FQ**, Ning J, Hao LX, Fan CX, Ning GJ, Yu HJ, Wang SW, Liu DW, Wang DY, Fu JP, Gou AL, Zhang GM, Huang GH, Chen YS, Mi SS, Liu YM, Yin DP, Zhu H, Fan XC, Li XL, Li KL, Tang HS, Xu WB, Wang Y, Yang WZ. Identification and Control of a Poliomyelitis Outbreak in Xijiang, China. **The New England Journal of Medicine**, 2013, 36(21).
117. Miao N, wang F, Chen Y, Zheng H, Wu Z, Gong X, **Cui F**. The investigation on knowledge and attitude of hepatitis B of vaccination staffs in 24 counties. *Chinese Journal of Vaccines and Immunization*, 2013, 19(4):329-331. (corresponding author)
118. Zhang L, Peng Z, Ou J, Zeng G, Fontaine R, Liu M, **Cui F**, Hong R, Zhou H, Huai Y, Chuang SK, Leung YH, Feng Y, Luo Y, Shen T, Zhu BP, Widdowson MA, Yu H.

- Protection by Face Masks against Influenza A(H1N1)pdm09 Virus on Trans-Pacific Passenger Aircraft, 2009. **Emerging Infectious Diseases**,2013, 19(9):1403-1409.
119. **Cui F**, Zhang G, Sun X. Analysis on Susceptibility of Hepatitis B Virus Infection among Population Aged between 15 and 59 in China, *Jiangsu J Prev Med*, 2013, 24(4):1-3.
  120. Zhang G, Sun X, Wang F, Zheng H, Gong X, Miao N, Jia Y, **Cui F**. Analysis of Epidemiological Characteristics of Hepatitis B of 18-59 Year-old Population and Hepatitis B Vaccine Recommendations. *Chinese Journal of Vaccines and Immunization*,2013,19(3):266-270.(corresponding author).
  121. Shen L, Gong X, Wang F, Zhang S, **Cui F**, Wang F, Yin W, Zhang Y, Liang X. Study on long term efficacy and duration of hepatitis B vaccine in China. *Chin J Microbiol Immunol* 2013,33(1):6-10.
  122. Wen N, Luo H, Wang H, **Cui F**, Zheng H, Wang F, Zhang Y, Fan C, Hao L, Ma C, Liu B. Study on Risk Assessment and Response of Wild Poliovirus Importation after Polio Imported into Xinjiang Uygur Autonomous Region. *Chinese Journal of Vaccines and Immunization*, 2013,19(3) :193-198.
  123. Zhang L, Yan B, Lv J, Liu J, Feng Y, Xu A, Gong X, **Cui F**, Liang X, Li B, Chen D, Ji X, Chen S. Assessment on Serological Survey of Antibody to Hepatitis B Virus Surface Antigen Response to Revaccination of 5 $\mu$ g Recombinant Hepatitis B Vaccine Derived from Yeast with Different Type,Different Dosage and Different Schedule among Low-response Infants after primary vaccination. *Chinese Journal of Vaccines and Immunization*, 2013,19(3) :250-254.
  124. Sun A, Wang F, Wang F, Zhang S, Tu Q, Shao X, Zheng H, Sun X, Gong X, Miao N, **Cui F**, Bi S, Chen Y. The Feasible Study of Hepatitis B Virus Surface Antigen Carriers Initiative Inform the Hepatitis B Virus Infection to the Spouse. *Chinese Journal of Vaccines and Immunization*, 2013,19(3) : 260-265.
  125. Miao N, Jin L, Piao H, Chen L, Wang F, Chen Y, Zheng H, Wu Z, **Cui F**, Li L, Liang X. Study on Risk Factors of Hepatitis C Virus Infection in Yanbian Korean Prefecture. *Chinese Journal of Vaccines and Immunization*, 2013,19(2) :159-163.
  126. Zhang Y, Luo H, Wen N, **Cui F**, Wang H. A Study of Risk Assessment Tool on Wild Poliovirus Importation and Transmission. *Chinese Journal of Vaccines and Immunization*, 2013,19(1) :17-19.
  127. Yin W, Wang F, Shen L, Wang X, Zhang S, Chen Y, **Cui F**, Bi S, Zhang Y. The Positive Correlation of Log Hepatitis B Virus (HBV) Deoxyribonucleic Acid Load and Log HBV e Antigen(HBeAg) and Log Antibody to HBeAg[J]. *Chinese Journal of Vaccines and Immunization*, 2012,18(4):.
  128. Du W, Zhou Y, Yue C, Xia W, Fan C, **Cui F**, Liang X. Intervention effect evaluation of inter-personal communication for immunization health education in western areas. *Chinese Journal of Health Education*[J]. *Chinese Journal of Vaccines and Immunization*,2012,18(8):
  129. Feng Y, Yan B, Lv J, Liu J, Gong X, **Cui F**, Liang X, Chen S, Xu A. Study on antibody response to revaccination of hepatitis B vaccine among firstly low-response adults. *Chin J Prev Med*, 2012,46(9): 813-818.



130. Liang X, **Cui F**. Technical guide for adult hepatitis B immunization in China. *Chinese Journal of Gastroenterology and Hepatology*, 2012,21(3):197-201.
131. Yan B, Zhang L, Lv J, Liu J, Feng Y, Ji F, Xu A, Chen S, Gong X, **Cui F**, Liang X. Comparison of the antibody response and related influencing factors after primary immunization by 10  $\mu$ g hepatitis B vaccine made from recombinant DNA techniques in *Saccharomyces cerevisiae* and *Hansenula polymorpha* among adults. *Chin J Epidemiol*, 2012,33(9):988-989.
132. Zhang L, Zhang W, Zhai X, Li Y, Li J, Yan B, Li Y, Zhu F, Huang T, Li L, Gong X, **Cui F**, Liang X, Xu A. Comparison on the antibody response after primary immunization of 5  $\mu$ g and 10 $\mu$ g hepatitis B vaccine made by recombinant DNA techniques among newborns. *Chin J Epidemiol*, 2012,33(3): 305-308.
133. Zhang L, Zhai X, Li Y, Li J, Yan B, Li Y, Zhu F, Huang T, Li L, Gong X, **Cui F**, Liang X, Xu A. Multi—center matching study on antibody response between preterm and full — term infants after primary immunization of hepatitis B vaccine. *Chin J Epidemiol*, 2012,33(2):185-190.
134. Xu Y, **Cui F**, Luo J, et al. Epidemiological characteristic analysis of hepatitis A in five northwestern provinces of China in 2011. *Chinese Journal of Vaccines and Immunization*, 2012, 18 (5):546-549. (corresponding author)
135. Ma H, He J, **Cui F**, Wang Y, Gong X, Chen Y, Wang F, Zheng H, Wu Z, Miao N, Sun X. Survey on the knowledge, attitude and Practice about medical workers in a comprehensive hospital in Gansu province. *Chinese Journal of Vaccines and Immunization*,2012,18(5):461-464. (corresponding author)
136. Chen Y, Liang X, Yao J, **Cui F**, Wang F, Shen L. Evaluation on booster immunization efficacy of 5  $\mu$ g hepatitis B vaccine made by recombinant deoxyribonucleic acid(DNA) techniques in *Hansenula polymorpha* yeast of variant dosage in children aged over 5 years old. *Chin Prev Med*, 2012,13(2):81-87.
137. Chen Y, Yao J, Liang X, **Cui F**, Wang F, Shen L. Evaluation on booster immunization efficacy of hepatitis A and B combined vaccine of one dosage in children. *Chin Prev Med*, 2012,13(4):256-259.
138. Du W, Zhou Y, Yue C, Xia W, Fan C, **Cui F**, Liang X. Intervention effect evaluation of inter-personal communication for immunization health education in western areas. *Chinese Journal of Health Education*, 2012,28(8):632-634.
139. Lv J, Yan B, Zhang L, Liu J, Feng Y, Xu A, Gong X, **Cui F**, Liang X, Jiang M, Chen D, Ji X, Chen S. Study on the Immune Response and Influencing Factors of Primary Immunization by 5 $\mu$ g Hepatitis B Vaccine Made by Recombinant DEXyribonucleic Acid Techniques in *Saccharomyces Cerevisiae* Yeast among Infants. *Chinese Journal of Vaccines and Immunization*, 2012,18(4):320-324.
140. Yin W, Wang F, Shen L, Wang X, Zhang S, Chen Y, **Cui F**, Bi S, Zhang Y. The Positive Correlation of Log Hepatitis B Virus (HBV) Deoxyribonucleic Acid Load and Log HBV e Antigen (HBeAg) and Log Antibody to HBeAg. *Chinese Journal of Vaccines and Immunization*, 2012,18(4):316-319.
141. Wang F, Gong X, **Cui F**, Chen Y, Zheng H, Wu Z, Li L, Luo H, Liang X. Analysis on risk factors of hepatitis B virus surface antigen prevalence among people aged 1-14 years in China. *Chinese Journal of Vaccines and Immunization*,

- 2012,18(2):118-122.
142. Sun X, **Cui F**, Gong X, Wang F, Chen Y, Zheng H, Wu Z, Miao N, Ma H, Luo M, Yu W, Su C, Qian Y, Yang Z, Mo F, Luo H, Liang X. Survey on preventing perinatal transmission of hepatitis B virus in Fuyuan county. *Chinese Journal of Vaccines and Immunization*, 2012,18(1):31-36.
  143. Zheng H, Wang F, Chen Y, **Cui F**, Gong X, Wu Z, Miao N, Luo H, Liang X. The Hepatitis B Prevalence and the Vaccination Statutes of the 1-14 Years-old Children in Eastern, Central and Western Areas of China. *Chinese Journal of Vaccines and Immunization*. 2012,18(1):19-25.
  144. Chen Y, Wang F, Zheng H, **Cui F**, Gong X, Wu Z, Miao N, Luo H, Liang X. The seroepidemiological study and vaccination status analysis on viral hepatitis B among population aged 1-59 years in six areas of China in 2006. *Chinese Journal of Vaccines and Immunization*. 2012,18(1):14-18.
  145. **Cui F**, Gong X, Chen Y, et al. Vaccination progress of hepatitis B vaccine and Epidemiology Changes of carrying rate hepatitis B surface antigen by province in China, 1992-2006. *Chinese journal of vaccine and immunization*, 2012,18 (1):6-13.
  146. Shen L, Zhang S, Wang F, Zhang Y, Zhang W, Yu T, Wang F, **Cui F**, Liang X, Bi S. Study on Effect and Duration of Hepatitis B Vaccine Made by Deoxyribonucleic Acid Techniques with *Saccharomyces Cerevisiae* Yeast after Long-term Vaccination. *Chinese Journal of Vaccines and Immunization*. 2012,18(1):1-5.
  147. Lv J, Yan B, Chen S, Xu A, Liu J, Feng Y, Gong X, **Cui F**, Liang X, Zhang L, Wang J. Antibody response and the influencing factors after revaccination with three doses of hepatitis B vaccines among low-response adults. *Journal of Shandong University(Health Sciences)*, 2012,50(11):126-132.
  148. **Cui F**, Luo H, Zhou L, Yin D, Zheng C, Wang D, Gong J, Fang G, He J, Jeffrey MacF, Yu H. Transmission of Pandemic Influenza A(H1N1) Virus in a Train in China. *J Epidemiol*, 2011,21(4):271-277.
  149. Shen L, Wang F, Wang F, et al. Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China [J]. *Vaccine*, 2012, 30(47):6623-6627.
  150. Chen Y, Liang X, Yao J, **Cui F**, Wang F, Shen L, Fang C, Chen R, Liu C, Zheng X. Evaluation on the immunology of plasma derived hepatitis B vaccine 11 to 14 years later among children in high and middle epidemic areas. *Chin J Prev M*, 2011,45(6):562-564.
  151. Chen Y, Liang X, Yao J, **Cui F**, Wang F, Shen L, Yan C, Zheng X. Evaluation on booster immunization efficacy of recombinant hepatitis B vaccine made by recombinant Deoxyribonucleic Acid Techniques in Chinese Hamster Ovary by different dosage in children. *Chin J Microbiol Immunol*, 2011,31(7): 657-658.
  152. Liu J, Yan B, Zhang L, Xu A, Lv J, Feng Y, Gong X, **Cui F**, Liang X, Li B, Chen D, Ji X, Chen S. Matching study on antibody response between preterm and full-term infants after primary immunization and revaccination of hepatitis B. *Chin J Epidemiol*, 2011,32(10):1055-1056.
  153. Chen Y, Li L, **Cui F**, Xing W, Wang L, Jia Z, Zhou M, Gong X, Wang F, Zheng H,

- Luo H, Bi S, Wang N, Yang W, Liang X. A sero-epidemiological study on hepatitis C in China. *Chin J Epidemiol*, 2011,32(9):888-891.
154. Ma Q, Zou Y, Zhang X, Liang S, Xiao H, Xie X, Mei S, Jia W, Zhang Y, **Cui F**, Wang F, Liang X. Estimation on the intangible cost and influencing factors for patients with hepatitis B-related diseases. *Chin J Epidemiol*, 2011,32(8): 764-767.
155. Chen Y, Liang X, Yao J, **Cui F**, Li Q, Jiang Z, Wang F, Fang C, Chen Y, Su M, Zheng X. Evaluation on the efficacy of recombinant hepatitis B vaccine booster immunization in 2789 children aged over 10 years. *Chin J Epidemiol*, 2011,32(3):252-255.
156. Ma Q, Zou Y, Zhang X, Liang S, Xiao H, Xie X, Mei S, Jia W, Zhang Y, **Cui F**, Wang F, Liang X. Analysis on the direct economic burden and influence factors of HBV-related diseases in Guangzhou. *Chin P Med*, 2011, 12(5):383-386.
157. Liang S, Zhang S, Ma Q, Xiao H, Xie X, Mei S, Hu D, Zhou B, Li B, **Cui F**, Wang F, Liang X. Study on the direct economic burden of hepatitis B and its economic impact on family in Shenzhen city. *Chinese Health Economics*, 2011,30(2):56-58.
158. **Cui F**, Wang F, Wu Z, Gong X, Chen Y, Zheng H, Miao N. Epidemiology analysis on reported hepatitis B in China, 2005-2010. *Chinese journal of vaccine and immunization*, 2011,17 (6):483-486.
159. Sun X, **Cui F**, Wang F, Chen Y, Zheng H, Wu Z, Miao N, Luo M, Yu W, Su C, Qian Y, Yang Z, Mo F, Liang X. Application and influences of prenatal screening for hepatitis B virus surface antigen among pregnant women in poverty areas. *Chinese Journal of Vaccines and Immunization*. 2011,17(5):408-435.
160. Zhang L, Yan B, Lv J, Liu J, Feng Y, Xu A, Gong X, **Cui F**, Liang X, Jiang M, Chen D, Ji X, Chen S. Response to revaccination of hepatitis B vaccine(HepB) with different doses and different schedule among non-response infants after 3 doses of 5 $\mu$ g HepB made by recombinant Deoxyribonucleic Acid techniques in *Saccharomyces Cerevisiae* yeast primary vaccination. *Chinese Journal of Vaccines and Immunization*. 2011,17(5): 395-398.
161. Yao J, Liang X, Chen Y, **Cui F**, Jiang Z, Li Q, Wang F, Shen L, Fang C, Chen R. Evaluation on Immune effect of hepatitis B vaccine Immunization among children aged 5-16 years in high epidemic areas of hepatitis B virus. *Chinese Journal of Vaccines and Immunization*. 2011, 17(4):294-298.
162. Sun X, **Cui F**, Gong X, Chen Y, Wang F, Zheng H, Wu Z, Miao N, Liang X. Progress towards preventing perinatal transmission of HBV. *Jiangsu J Prev Med*,2011,22(5):66-70.
163. Shen L, Chen Y, Jiang Z, Li Q, Chen E, Liang X, **Cui F**, Yao J. Evaluation on booster immunization efficacy of 10 $\mu$ g recombinant hepatitis B vaccine made by recombinant Deoxyribonucleic Acid Techniques in *Hansenula Polymorpha* Yeast by different dosage in children. *Disease Surveillance*, 2011,26(10):811-814.
164. **Cui F**. The best immunization strategy of hepatitis B vaccine in China. The 15th national conference on viral hepatitis and liver diseases.2011.
165. **Cui F**, Li L, Hadler S, Wang F, Zheng H, Chen Y, Gong X, Hutin Y, Cairns K, Liang X, Yang W. Factors Associated with Effectiveness of the First Dose of Hepatitis B Vaccine in China:1992-2005. *Vaccine* 28 (2010) 5973–5978.

166. Yin J, Zhang H, He Y, Xie J, Liu S, Chang W, Tan X, Gu C, Lu W, Wang H, Bi S, **Cui F**, Liang X, Schaefer S, Cao G. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. *Cancer Epidemiol Biomarkers Prev.* 2010,19(3):777-86.
167. Liang S, Zhang S, Ma Q, Xiao H, Lv Q, Xie X, Mei S, Hu D, Zhou B, Li B, Chen J, **Cui F**, Wang F, Liang X. Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China. *Chin J Epidemiol*, 2010,31(12): 1340-1345.
168. Zheng H, **Cui F**, Gong X, Wang F, Chen Y, Wu Z, Wang H, Li L, Luo H, Liang X. Status of the hepatitis B virus surface antigen and e antigen prevalence among reproductive women in China. *Chinese Journal of Vaccines and Immunization.* 2010,16(6):496-499.
169. Liu Y, Chen Y, **Cui F**, Wang F, Zheng H, Wu Z, Miao N, Luo H, Liang X, Gong X. Epidemiological analysis of hepatitis A in China during 2004-2009. *Chinese Journal of Vaccines and Immunization.* 2010, 16(5):453-456.
170. Zheng H, **Cui F**, Gong X, Wang F, Chen Y, Wu Z, Zhang W, Dong H, Shao X, Zhang Y, Liang X. Revaccination of one dose recombinant yeast derived hepatitis B vaccine to the antibody respond of low-and-nonresponders. *Chinese Journal of Vaccines and Immunization.* 2010,16(5):443-446.
171. Qi K, Li H, Gao L, Zhang X, **Cui F**, Yoshihiro Takashima, Ni D, Peng B. Study on the timely birth dose of hepatitis B vaccine and the influencing factors among children born in 2005 in Dingxi prefecture. *Soft Science of Health*,2010,24(2):145-148.
172. Cui F. PP071 Evaluation of the impact of hepatitis B vaccination among children born between 1992 and 2005 in China[J]. *International Journal of Infectious Diseases*, 2009, 13(09):S68-S69.
173. **Cui F**, Hadler S, Zheng H, Wang F, Wu Z, Hu Y, Gong X, Chen Y, Liang X. Status of hepatitis A surveillance and vaccine use in China from 1990 through 2007. *J Epidemiol*, 2009;19(4):189-195.
174. Liang X, Bi S, Yang W, Wang L, Cui G, **Cui F**, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler S, Wang Y. Evaluation of the Impact of Hepatitis B Vaccination among Children Born during 1992 and 2005 in China. *Journal of Infectious disease*, 2009,200(1):39-47.
175. Liang X, Bi S, Yang W, Wang L, Cui G, **Cui F**, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler S, Wang Y. Epidemiological Serosurvey of Hepatitis B in China - Declining HBV Prevalence due to Hepatitis B Vaccination. *Vaccine*, 2009, 27:6550-6557.
176. Wang F, **Cui F**, Liu D, Gong X, Zheng H, Chen Y, Liang X. Analysis on the adverse events following immunization of 10 infants death after hepatitis B vaccination. *Chinese Journal of Vaccines and Immunization*, 2009,15 (1): 52-57.
177. **Cui F**, Gong X, Chen Y, Wang F, Zheng H, Hu Y, Wu Z, Miao N, Li L, Liang X. Evaluation on impact of hepatitis B vaccine integrated into routine immunization in the areas of Ministry of Health/Global Alliance for vaccine and

- Immunization(GAVI) cooperation project P.R.China. Chinese Journal of Vaccines and Immunization, 2009,15 (4): 289-293.
178. **Cui F**, Bi S, Zhang Y, Gong X, Chen Y, Wang F, Zheng H, Jia Z, Hu Y, Wu Z, Miao N, Li L, Liang X. Combination profiles of hepatitis B marks for Chinese in Serosurvey in 2006. Chinese Journal of Vaccines and Immunization, 2009,15(4): 294-299.
  179. Zheng H, **Cui F**. The immunogenicity and impact factors of hepatitis A attenuated live vaccine and inactivated vaccine. Chinese Journal of Vaccines and Immunization, 2009,15 (4): 371-374.
  180. **Cui F**, Miao N, Hu Y, Duan J, Zhong J, Wang X, Li J. Effect of hepatitis B health promotion project in schools of Beijing and Gansu. Chinese Journal of Vaccines and Immunization, 2009,15 (5): 409-416.
  181. Dang R, Zhang S, Zhang W, Liang X, **Cui F**, Zhao F. Assessment for immune effectiveness of hepatitis B vaccination among infant population in China. Chin J Public Health., 2009,25(4): 385-387.
  182. Zhang S, Dang R, Zhang W, Liang X, **Cui F**. Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China. Chin J Epidemiol, 2008,29(10):1003-1008.
  183. Chen Y, Li F, Wang X, Wang F, **Cui F**, Gong X, Zheng H, Zeng S, Zhao J, Xie J, Chen C, Xia W, Sun L, Zhang Y, Xiao N, Hu Y, Wu Z, Liang X. Study on the probability of hepatitis B virus infection at public service places. Chin J Epidemiol, 2008,29(7):689-692.
  184. **Cui F**, Gong X, Chen Y, Wang F, Zheng H, Hu Y, Wu Z, Wang H, Liang X. Chinese Hepatitis B Immunization Strategies and Feasibility of Expanding the Vaccination to Children and High Risk Population among Adult. Chinese journal of vaccine and immunization 2008,14(6):553-558.
  185. Wu Z, **Cui F**, Gong X, Chen Y, Wang F, Zheng H, Hu Y, Liang X. Influential factors of non-and-low response after hepatitis B vaccination to infants. Chinese journal of vaccine and immunization, 2008,14(5):464-469.
  186. **Cui F**, Wang F, Zheng H, Chen Y, Gong X, Wang H, Liang X. Analysis on Reported Cases of Hepatitis B in China in 2005-2007. Chinese journal of vaccine and immunization, 2008,14(5):413-417.
  187. Chen Y, Zhou Y, Wang X, Chen C, Li F, Wang F, Zeng S, Zhao J, Xie J, **Cui F**, Gong X, Zheng H, Xia W, Sun L, Zhang Y, Xiao N, Hu Y, Wu Z, Cao L, Liang X, Hu J. Study on the status of sanitizing and HBV contamination of appliances used in the public service places. Chinese journal of vaccine and immunization, 2008,14(4):315-318.
  188. Liang X, Yang C, Luo H, Wang H, **Cui F**, Li Y, Du F, An Z, Yin D, Liu D, Cao L, Yin Z, Zheng H, Yang F, Cui G, Yang W. Analysis on mass vaccination campaign of hepatitis A vaccine and live Japanese Encephalitis vaccine in earthquake areas in Sichuan. Chinese journal of vaccine and immunization, 2008,14(4):289-291.
  189. Hu Y, Zhang Y, Wan M, Li C, Li X, **Cui F**, Gong X, Chen Y, Wang F, Zheng H, Liang X. Evaluation of sustainability of the project of improving timely birth dose of hepatitis B vaccine in Tibetan autonomous prefecture of Huangnan. Chinese

- journal of vaccine and immunization, 2008,14(2):147-149.
190. **Cui F**, Wang X, Cao L, Liang X, Lu Y, Hu Y, Hadler S, Shapiro CN, Wiersma ST, Ward JW. Progress in Hepatitis B Prevention Through Universal Infant Immunization — China, 1997–2006. *MMWR*, 2007,56(18): 441-445.
  191. **Cui F**, Wang X, Cao L, Liang X, Lu Y, Hu Y, Hadler S, Shapiro CN, Wiersma ST, Ward JW. Progress in Hepatitis B Prevention Through Universal Infant Vaccination-China, 1997-2006. *Wkly Epidemiol Rec*, 15 June 2007, 82(24) (Reprinted):209-224.
  192. **Cui F**, Wang X, Cao L, Liang X, Lu Y, Hu Y, Hadler S, Shapiro CN, Wiersma ST, Ward JW. Progress in Hepatitis B Prevention Through Universal Infant Vaccination-China, 1997-2006. *JAMA*, 2007,298( 5) (Reprinted): 506-509.
  193. **Cui F**, Gaofin R. Immunization coverage and its determinants in children aged 12–23 months in Gansu, China. *Vaccine*, 2007, 25(4):664-671.
  194. **Cui F**, Lu Y, Wang F, Chen Y, Zheng H, Zhang Y, Gong X, Han L, Dong H, Chen C, Ling L, Zhang L, Diao L, Shao X, Fang G, Gao L, Liang X. Analysis on the proportion of reported Hepatitis B cases through pilot surveillance in China during 2006. *Chinese Journal of Epidemiology*, 2007, 28(9):872-874.
  195. Sui H, Liang X, Yin D, **Cui F**, Wang H. Epidemic characteristics on Hepatitis A in China during 1990~2006. *Chinese Journal of Vaccines and Immunization*,2007, 13(5):466-469.
  196. Zheng H, Lu Y, Wang F, **Cui F**. Epidemiological analysis on Hepatitis A in China during 2004~2006. *Chinese Journal of Vaccines and Immunization*. 2007, 13(4): 336-340.
  197. **Cui F**, Hu Y, Lu Y, Pur H, Chen Y, Li J, Zheng H. Analysis on timely birth dose coverage among infant born in different places in western provinces of China. *Chinese Journal of Vaccines and Immunization*,2007, 13(4): 313-315
  198. Wang F, **Cui F**, Lu Y, Chen Y, Zheng H, Liang X. Analysis on reported Hepatitis B cases on pilot surveillance in 18 counties of 8 provinces of China. *Chinese Journal of Vaccines and Immunization*,2007,13(4):309-312.
  199. Wang F, **Cui F**, Zheng H, Chen Y, Li J, Gong X, Fang T, Gao L, Zhang Y, Liang X. Evaluation on protective efficacy of recombinant yeast derived Hepatitis B vaccines combination with Hepatitis B immune globulin in preventing mother-to-infant transmission of Hepatitis B virus. *Chinese Journal of Vaccines and Immunization*, 2007,13(4):293-297.
  200. **Cui F**, Wang F, Zheng H, Chen Y, Li J, Gong X, Fang T, Gao L, Zhang Y, Liang X. Evaluation on protective efficacy of recombinant yeast derived Hepatitis B vaccine in preventing mother-to-infant transmission of Hepatitis B. *Chinese Journal of Vaccines and Immunization*, 2007,13(4):289-292.
  201. **Cui F**, Li T, Guo Q. Review on immunization coverage assessment in different studies. *Chinese Journal of Vaccines and Immunization*,2007,13(2): 170-174.
  202. Li X, Wan M, Li Q, Li C, Hu Y, Zhang Y, Qiao H, Wang J, Ma Y, **Cui F**, Liang X, Ni D, Yoshihiro Takashima. Analysis on health education on improving the timely-birth dose coverage of Hepatitis B in rural and pasturing areas in Qinghai province. *Chinese Journal of Vaccines and Immunization*, 2007,13(1):43-45.

203. Zhang Y, Hu Y, Zhang X, Shi X, Wan M, Li Q, Li C, Li X, **Cui F**, Liang X, Ni D, Yoshihiro Takashima. Strategy on improving the birth-time coverage in Huangnan prefecture of Qinghai province. *Chinese Journal of Vaccines and Immunization*, 2007,13(1):40-42.
204. Li C, Wan M, Li X, Zhang Y, Zhang X, Ba W, Li Q, Qiao H, Ma Y, **Cui F**, Liang X, Yoshihiro Takashima, Ni D. Study on birth-time coverage and correlative factors in Huangnan prefecture of Qinghai province in 2004. *Chinese Journal of Vaccines and Immunization*, 2007,13(1):37-39.
205. Chen Y, Wang X, Li Y, **Cui F**, Liang X. Analysis on the Investigation about the prevalence rate of chronic HBV infection. *Chinese Journal of Vaccines and Immunization*, 2007;13(1):27-29.
206. **Cui F**, Pur H, Hadler S, Liang X. Analysis on new born Hepatitis B immunization coverage and pregnant women hospital delivery rate in different regions. *Chinese Journal of Vaccines and Immunization*, 2007,13(1): 1-3.
207. **Cui F**, Liang X, Cao L, et al. Improving Hepatitis B immunization rates in China. *JOURNAL OF CLINICAL VIROLOGY*,2006,36(s):237.
208. Lu Y, **Cui F**, Wang X, Gong X, Dong H, Hu Y, Chen Y, Liang X. Capacity of laboratory testing for acute hepatitis B in medical setting in 8 provinces in China. *Chinese Journal of Epidemiology*, 2006, 27 (9):802-804.
209. **Cui F**, Lu Y, Hu Y, Chen Y, Hadler S, Cao L, Liang X, Cui G. Analysis on Hepatitis B vaccine integration into national immunization programme for children in China. *Chinese Journal of Vaccines and Immunization*, 2006,12(4):241-245.
210. **Cui F**, Wang X, Liang X. Epidemiological analysis on reported Hepatitis B under 15 years in China. *Chinese Journal of Vaccines and Immunization*, 2006,12(3):206-208.
211. Hu Y, Wang X, Chen Y, Lu W, Zhang R, **Cui F**, Li J, Zhou Y, Lu Y, Zhu B, Liang X. Study on Hepatitis B birth dose coverage in the western and mid-level provinces of China. *Chinese Journal of Vaccines and Immunization*, 2006, 12 (2): 206-208.
212. **Cui F**, Liang X, Lu Y, Hadler S. Analysis on Hepatitis B Immunization Coverage in 12 Western Provinces in China. *Chinese Journal of Vaccines and Immunization*, 2006,12(2): 81-83.
213. Gao L, Li H, Zhang X, **Cui F**, Liu J, Tang Y, Li X, Wang X, Lu X. Analysis on immunization coverage rate and affecting factors of Hepatitis B vaccine among children in Gansu province in 2001-2003. *Chinese Journal of Vaccines and Immunization*, 2006, 12(2):106-108.
214. Zhang N, Fu H, Li H, **Cui F**. Analysis on the Epidemiology of measles surveillance in 2003 in Gansu province. *Chinese Journal of Vaccines and Immunization*,2005, 11(3):192-194.
215. **Cui F**, Li H, Meng L, Wang J, Liu J, Li F, Lu X, Shu A. Study on the vaccination rate and its influencing factors among children aged between 12 to 23 months in Gansu province. *National achievement of science and technology*, 2005.
216. Li H, Li F, Zhen X, Wu Z, Tang Y, **Cui F**, Zhang N, Liu J, Fu H, Wang X, Gao L, Zhang X, Li X. Progress of maintaining polio-free status in Gansu. *Chinese Journal of Vaccines and Immunization*,2005, 11(1): 61-63.

217. Ishikawa N, Hao L, Zhang Z, **Cui F**, Li H. The factors affecting the low coverage rate of hepatitis B vaccine at birth and the role of health education in Gansu province, China. *Chinese Journal of Vaccines and Immunization*, 2004, 10(3):138-141.
218. Zhang N, Fu H, Li H, **Cui F**. Analysis and evaluation on measles surveillance data of Gansu province in 2003. *Health Vocational Education*, 2004, 22(17):113.
219. Li H, Zhi H, Fu H, **Cui F**, Gao L, Sun Y. Evaluation on efficacy of measles vaccine immunization campaign in partial areas of Gansu province. *Chin J Public Health*, 2003, 19(6):739.
220. Li H, Fu H, Di H, **Cui F**, Sun Y, Liu J. Evaluation on serological efficacy of measles vaccine immunization campaign in partial areas of Gansu province. *Chinese Journal of Vaccines and Immunization*, 2003, 9(5):266-268.
221. **Cui F**, Tang Y, Lu X, Zhang N. Survey on establishing computer based system on cold chain management, *Chinese Journal of Vaccines and Immunization*, 2003, 9(5):258.
222. Meng L, Li H, Liu J, Gao L, **Cui F**, Lu X. The epidemiological features of hepatitis B in Gansu province and the control strategy. *Chinese Journal of Vaccines and Immunization*, 2003, 9(6): 326-328.
223. He G, Li H, **Cui F**, Zhi H, Fu H, Li F, Liu J, Shao A. An analysis on immunization coverage rate of Children in different economic developing areas in Gansu Province. *Chinese Journal of Vaccines and Immunization*, 2002, 8(4):217-219.
224. **Cui FQ**, Di HJ, Li H, et al. Progress on polio eradication in Gansu, China in 2001. *Chinese journal of vaccine and immunization*, 2002, 8(s): 17—18.
225. Li H, He G, **Cui F**, Liu J, Li F, Shi H. Investigation on immunization serves at grass root level in Gansu province. *Chinese Journal of Vaccines and Immunization*, 2001, 7(3):172-174.
226. **Cui F**, He G, Li H. Evaluation on the project of neonatal tetanus elimination in Gansu, *Chinese Journal of Vaccines and Immunization*, 2001, 7(3): 152-154.
227. Li H, He G, **Cui F**. An investigation on present situation of safe injection of immunization service in different economic areas in Gansu province. *Chinese Journal of Vaccines and Immunization*, 2001, 7(4):218-220.
228. **Cui F**. Survey on status of cold chain in Gansu. *Chinese Journal of Epidemiology*, 1997, 18(1-C): 141-145.

#### **D. Research Support**

- 10<sup>th</sup> Five Year Plan on Science and research in 2006, Grant Number: 2004BA718B01
- 11<sup>th</sup> Five Year Plan of National Key Research Project of Science and Technical in 2009: 19.65 million RMB, Grant Number: 2008ZX10002-001
- 12<sup>th</sup> Five Year Plan of National Key Research Project of Science and Technical in 2012: 8.3469 million RMB, Grant Number: 2012ZX10002001



## **E. Oral presentations at international conferences**

- The latest development of Covid-19 vaccine. Fifth Annual QU Health Research Symposium. 14 November 2020. Qatar & PKU.
- Global and regional progress towards hepatitis elimination. 29-30 June 2020, Geneva, WHO Validation meeting on hepatitis elimination as a public health threat: Part 1.
- Latest developments in global hepatitis B control. Third Consultation of the South-East Asia Regional Expert Panel for Verification of Hepatitis B Control (SEA-REP) New Delhi, India, 20-21 January 2020.
- China's work towards elimination of hepatitis B virus. Sixth Hepatitis B Immunization Expert Resource Panel (ERP) Consultation. World Health Organization, West Pacific Region Office, Sep 18, 2018. Manila, Philippine.
- Fostering collaboration among MCH, NIP and HSI in China. Sixth Hepatitis B Immunization Expert Resource Panel (ERP) Consultation. World Health Organization, West Pacific Region Office, Sep 18, 2018. Manila, Philippine.
- Developing a Healthcare Worker Vaccination Programme in China. Sixth Hepatitis B Immunization Expert Resource Panel (ERP) Consultation. World Health Organization, West Pacific Region Office, Sep 18, 2018. Manila, Philippine.
- New Development of Preventing Mother-to Child HBV Transmission in China. Fifth Hepatitis B Immunization Expert Resource Panel (ERP) Consultation WHO WPRO ERP, Manila, Philippine. 2017
- What Can We Learn from Hepatitis B and C Control in China, Current Progress and Future Considerations? First Meeting of Hepatitis Programme Focal Points from High-burden Countries in Asia. Hong Kong SAR (China), June 22-24, 2016. Hong Kong, China.
- What Can We Learn from Hepatitis B Control in China? The 3<sup>rd</sup> International Symposium on Viral Hepatitis. June 22-24, 2016. Chengdu, China.
- Review of 2014 sero-survey results and next steps in hepatitis B control in China, 2014. The Fourth Meeting of Experts Resources Panel, WHO, Western Pacific Region. January 25-27, 2016. Hanoi, Viet Nam
- Introduction on China's National Immunization Programme, Chairperson and Speaker on The Second China-Czech Health Forum, session of Public Health: Priority of Czech-China Health Cooperation June 20, 2014. Beijing, China.
- Measles Elimination in China: Strategies, Progress, Challenges and Action Plans. World Health Organization SAGE Decade of Vaccines Working Group Meeting. 18-20 February 2014, WHO HQ Geneva.
- Progress and challenges to Care: Treatment, management, and care strategies in China. HCV Treatment and care in vulnerable populations: Challenges, opportunities and future directions, November 7-7, 2013. Ottawa, Canada.
- Scaling up hepatitis B vaccination with the support of GAVI in China: Lessons learned for introduction of new vaccines and for the future of hepatitis B control. Life & Health R&D Forum: infectious diseases and vaccination, Beijing China, August 15, 2013.
- Viral Hepatitis surveillance in China. Technical Consultation to Develop Guidelines for the Surveillance of Viral Hepatitis in Low- and Middle-income Countries. World Health Organization Headquarters, Geneva, 25-27 March 2013

- Chinese Experience on Improving Hepatitis B vaccine Time Birth Dose of Public Health Innovation through Collaboration. Guest speaker for CDC-China Focus, 23 January 2013, Beijing American Center, Beijing, China
- Progress toward Measles Elimination in China. 21th Technical Advisory Expert Group Meeting on Vaccines and Vaccine preventable Disease in WPRO. 21–23 August 2012, Manila, Philippines
- Overview of China Experience with Increasing Timely Birth Dose. Consultation on improving and monitoring Hepatitis B birth dose. 13-15 June 2012, WPRO, Manila, Philippines
- Progress toward Measles Elimination in China: Achievement and Challenges. WHO Western Pacific Region Technical Advisory Group meeting, 9 August, 2011, Manila, Philippine.
- Experience with measles elimination in high epidemic areas in China. WHO Western Pacific Region Technical Advisory Group meeting, 9 August, 2011, Manila, Philippine.
- Consultation on Best Practices and Tools for Preventing Perinatal Hepatitis B Virus Transmission. Burnet Institute, Melbourne, Australia, 7-8 December 2010.
- Post-marketing surveillance of the live attenuated hepatitis A vaccines in China, Global Advisory Committee on Vaccine Safety, 16-17 June 2010, Geneva.
- Evaluation plans for GAVI project in China, and catch up vaccination in children, Asia and viral hepatitis: Learning from China to enhance prevention and control efforts in Asia. April 28, 2010, Hongkong, China
- Impact of hepatitis A vaccine use on disease incidence in China, Asia and viral hepatitis: Learning from China to enhance prevention and control efforts in Asia. April 28, 2010, Hongkong, China
- Hepatitis B control, Strategies, successes and challenges in China. Scientific seminar on hepatitis B, 26-27 Jan 2010, Hanoi, Vietnam.
- Progress of Measles Control in China, Global Measles Management Meeting, 20 February, 2009, New York, USA.
- Evaluation on Health Promotion Program in China, 11 Feb, 2009. Hong Kong.
- Hepatitis B in China: Example of How to Tackle Discrimination, Asia Summit on Corporate society Responsibility, 3 Nov, 2008, Thailand.
- Achievability of Regional Goal - Strategies, Successes and Challenges, WPRO Technical Advisory Group meeting, 27 June, 2007, Manila, Philippine.
- Operational Features of China - Hepatitis B Immunization Program, WPRO Technical Advisory Group meeting, 20 June, 2006, Manila, Philippine.
- Improving Hepatitis B Immunization Rates in China, 12th International Conference for Hepatitis, 4 July, 2006, Paris, France.
- Hepatitis B Vaccination in China, Annual Meeting of Asian and Pacific Association of Study of Liver, 17 August, 2005, Bali, Indonesia.